Long residence time inhibition of EZH2 in activated polycomb repressive complex 2

ACS Chemical Biology

Volumn 9, Issue 3, 2014, Pages 622-629

  Van Aller, Glenn S ^a   Pappalardi, Melissa Baker ^a   Ott, Heidi M ^a   Diaz, Elsie ^b   Brandt, Martin ^b   Schwartz, Benjamin J ^b   Miller, William H ^a   Dhanak, Dashyant ^a   McCabe, Michael T ^a   Verma, Sharad K ^a   Creasy, Caretha L ^a   Tummino, Peter J ^a   Kruger, Ryan G ^a  

^a Cancer Research   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRONE; HISTONE H1; HISTONE H3; LYSINE; POLYCOMB REPRESSIVE COMPLEX 2; S ADENOSYLMETHIONINE; TRANSCRIPTION FACTOR EZH2; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; GSK126; INDOLE DERIVATIVE; NUCLEOSOME; PROTEIN BINDING; PYRIDONE DERIVATIVE;

ALKYLATION; AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CELL MUTANT; CHROMATIN; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DILUTION; DISSOCIATION; DISSOCIATION CONSTANT; DNA SEQUENCE; ENZYME ACTIVATION; ENZYME ACTIVITY; EPIGENETICS; HISTONE METHYLATION; IC 50; IN VIVO STUDY; INHIBITION KINETICS; ISOMERIZATION; METHYLATION; NONHODGKIN LYMPHOMA; NUCLEOSOME; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; STEADY STATE; STRUCTURE ACTIVITY RELATION; WILD TYPE; ALLOSTERISM; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; HELA CELL LINE; HUMAN; TIME;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HELA CELLS; HUMANS; INDOLES; METHYLATION; NUCLEOSOMES; POINT MUTATION; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BINDING; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 84896928662     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4008748     Document Type: Article

References (23)

1. McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., Chen, S. B., la Pietra, A., Dul, E., Hughes, A. M., Gilbert, S. A., Thrall, S. H., Tummino, P. J., Kruger, R. G., Brandt, M., Schwartz, B., and Creasy, C. L. (2012) Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) Proc. Natl. Acad. Sci. U.S.A. 109, 2989-2994
2. Yap, D. B., Chu, J., Berg, T., Schapira, M., Cheng, S.-W. G., Moradian, A., Morin, R. D., Mungall, A. J., Meissner, B., Boyle, M., Marquez, V. E., Marra, M. A., Gascoyne, R. D., Humphries, R. K., Arrowsmith, C. H., Morin, G. B., and Aparicio, S. A. J. R. (2011) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation Blood 117, 2451-2459
3. McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., LaFrance, L. V., Mellinger, M., Duquenne, C., Tian, X., Kruger, R. G., McHugh, C. F., Brandt, M., Miller, W. H., Dhanak, D., Verma, S. K., Tummino, P. J., and Creasy, C. L. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 492, 108-112
4. Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H., Lin, Y., Gu, J., Ardayfio, O., Zhang, J. H., Yan, X., Fang, J., Mi, Y., Zhang, M., Zhou, T., Feng, G., Chen, Z., Li, G., Yang, T., Zhao, K., Liu, X., Yu, Z., Lu, C. X., Atadja, P., and Li, E. (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation Proc. Natl. Acad. Sci. U.S.A. 109, 21360-21365
5. Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., Scott, M. P., Jin, L., Smith, J. J., Olhava, E. J., Chesworth, R., Moyer, M. P., Richon, V. M., Copeland, R. A., Keilhack, H., Pollock, R. M., and Kuntz, K. W. (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells Nat. Chem. Biol. 8, 890-896
6. Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury, W. J., III, Voigt, P., Martin, S. R., Taylor, W. R., De Marco, V., Pirrotta, V., Reinberg, D., and Gamblin, S. J. (2009) Role of the polycomb protein EED in the propagation of repressive histone marks Nature 461, 762-767
7. Claudio, C., Gabriel, C. L., Alessio, M., Franz, H., Ruedi, A., and Eva, N. (2012) Molecular architecture of human polycomb repressive complex 2 eLife 1 e00005
8. Segel, I. H. (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, John Wiley & Sons, New York.
9. Young, N. L., DiMaggio, P. A., Plazas-Mayorca, M. D., Baliban, R. C., Floudas, C. A., and Garcia, B. A. (2009) High throughput characterization of combinatorial histone codes Mol. Cell. Proteomics 8, 2266-2284
10. Schmitges, F., Prusty, A., Faty, M., Stützer, A., Lingaraju, G., Aiwazian, J., Sack, R., Hess, D., Li, L., Zhou, S., Bunker, R., Wirth, U., Bouwmeester, T., Bauer, A., Ly-Hartig, N., Zhao, K., Chan, H., Gu, J., Gut, H., Fischle, W., Müller, J., and Thomä, N. (2011) Histone methylation by PRC2 is inhibited by active chromatin marks Mol. Cell 42, 330-341
11. Simon, M. D., Chu, F., Racki, L. R., de la Cruz, C. C., Burlingame, A. L., Panning, B., Narlikar, G. J., and Shokat, K. M. (2007) The site-specific installation of methyl-lysine analogs into recombinant histones Cell 128, 1003-1012
12. Jia, G., Wang, W., Li, H., Mao, Z., Cai, G., Sun, J., Wu, H., Xu, M., Yang, P., Yuan, W., Chen, S., and Zhu, B. (2009) A systematic evaluation of the compatibility of histones containing methyl-lysine analogues with biochemical reactions Cell Res. 19, 1217-1220
13. Seeliger, D., Soeroes, S., Klingberg, R., Schwarzer, D., Grubmüller, H., and Fischle, W. (2011) Quantitative assessment of protein interaction with methyl-lysine analogues by hybrid computational and experimental approaches ACS Chem. Biol. 7, 150-154
14. Martin, C., Cao, R., and Zhang, Y. (2006) Substrate preferences of the EZH2 histone methyltransferase complex J. Biol. Chem. 281, 8365-8370
15. Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., and Copeland, R. A. (2010) Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas Proc. Natl. Acad. Sci. U.S.A. 107, 20980-20985
16. Morrison, J. F. J. (1988) The behavior and significance of slow-binding enzyme inhibitors Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-301
17. Verma, S. K., Tian, X., LaFrance, L. V., Duquenne, C., Suarez, D. P., Newlander, K. A., Romeril, S. P., Burgess, J. L., Grant, S. W., Brackley, J. A., Graves, A. P., Scherzer, D. A., Shu, A., Thompson, C., Ott, H. M., Aller, G. S. V., Machutta, C. A., Diaz, E., Jiang, Y., Johnson, N. W., Knight, S. D., Kruger, R. G., McCabe, M. T., Dhanak, D., Tummino, P. J., Creasy, C. L., and Miller, W. H. (2012) Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2 ACS Med. Chem. Lett. 3, 1091-1096
18. Lu, H. and Tonge, P. J. (2010) Drug-target residence time: critical information for lead optimization Curr. Opin. Chem. Biol. 14, 467-474
19. Copeland, R. A. R. (2011) Conformational adaptation in drug-target interactions and residence time Future Med. Chem. 3, 1491-1501
20. Tummino, P. J. and Copeland, R. A. (2008) Residence Time of Receptor-Ligand Complexes and Its Effect on Biological Function Biochemistry 47, 5481-5492
21. Basavapathruni, A., Jin, L., Daigle, S. R., Majer, C. R. A., Therkelsen, C. A., Wigle, T. J., Kuntz, K. W., Chesworth, R., Pollock, R. M., Scott, M. P., Moyer, M. P., Richon, V. M., Copeland, R. A., and Olhava, E. J. (2012) Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L Chem. Biol. Drug Des. 80, 971-980
22. Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 5, 730-739
23. Luger, K., Rechsteiner, T. J., and Richmond, T. J. (1999) Expression and purification of recombinant histones and nucleosome reconstitution, in Chromatin Protocols, pp 1-16, Springer, New York.